Last updated on December 2019
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
Brief description of study
The main purpose of study is to compatibility the pharmacokinetic (PK) of Process D relative to Process C.
Detailed Study Description
The study is intended to compare the pharmacokinetic of Process D nivolumab to Process C nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV melanoma.
Clinical Study Identifier: NCT03980314